Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > BUSINESS
BUSINESS
- Tivantinib Fails Japan PIII Trial for HCC: Kyowa Kirin
March 28, 2017
- Nippon Shinyaku Gets Exclusive Japan Rights to Novel AML Drug
March 27, 2017
- Chugai Notches Supreme Court Victory in Oxarol Patent Suit
March 27, 2017
- AZ Gets Asian Rights to Kyowa Kirin’s Benralizumab
March 27, 2017
- Nobelpharma to Copromote Nobelzin with ASKA, Medipal upon Hypozincemia Nod
March 27, 2017
- EMA Accepts Schizophrenia Med Brexpiprazole for Review: Otsuka/Lundbeck
March 27, 2017
- Torii Seeks Pediatric Indication for Allergen Immunotherapy Miticure
March 27, 2017
- Shionogi Gets FDA Nod for Naldemedine
March 27, 2017
- Hit Compounds Enter POC Evaluation Stage in DNDi’s NTD Drug Discovery Booster Project
March 27, 2017
- Alexion Files Soliris for Refractory gMG
March 24, 2017
- Takata, Meiji Settle Patent Suit with Toyama Chemical over Pediatric Ozex Drug
March 24, 2017
- Wholesale Dealer President Deeply Sorry for Letting Fake Harvoni into Supply Chain
March 24, 2017
- Koshiya Tapped as Global Head of Oncology: Sumitomo Dainippon
March 23, 2017
- Japan Begins Using PD-L1 Expression Biomarker for Immune Checkpoint Inhibitors, but Challenges Linger
March 22, 2017
- US Biotech X-Chem Inks Collaboration Deals with Astellas, Ono
March 22, 2017
- Praluent Shows Consistent Efficacy, Safety in Diabetic and Non-Diabetic Patients: Japanese Subanalysis
March 22, 2017
- Ribomic Links Up with Astellas for Research on Development of Aptamer Therapy
March 22, 2017
- Hitachi Chemical to Buy US Cell Therapy Contract Manufacturer, Japan-Bound Operations Slated for FY2018
March 21, 2017
- Daiichi Sankyo, NIBIOHN Hook Up in Cancer Immunology with Mitsubishi Funding
March 17, 2017
- Novartis Vows Continued Reforms despite Not-Guilty Diovan Ruling
March 17, 2017
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…